|Bid||44.90 x 1200|
|Ask||44.91 x 1000|
|Day's range||44.70 - 45.14|
|52-week range||32.83 - 45.86|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||19.15|
|Earnings date||25 Oct 2021 - 29 Oct 2021|
|Forward dividend & yield||1.56 (3.45%)|
|Ex-dividend date||29 Jul 2021|
|1y target est||43.32|
Dr. Elizabeth Clayborne, UM Capital Region Medical Center Emergency Physician, joined Yahoo Finance Live to breakdown the latest COVID-19 headlines.
The Competition and Markets Authority has provisionally found that Flynn and Pfizer charged illegal prices for an anti-epilepsy treatment.
Pfizer (NYSE: PFE) recently provided its second-quarter update. In this Motley Fool Live video recorded on July 28, Motley Fool contributors Keith Speights and Brian Orelli discuss what really mattered in Pfizer's Q2 results. Keith Speights: Well in our last few minutes Brian, let's touch on the big earnings story from this morning and it has to do with Pfizer.